- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05166954
Effect of Bariatric Surgery on Cardiac Function in Patients With Hypertension
August 6, 2023 updated by: Beijing Friendship Hospital
The purpose of this study is to investigate the effect of bariatric surgery on cardiac function assessed by echocardiography in patients with hypertension.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
Obesity is the most common chronic metabolic disease worldwide, causing the increasing burden of cardiovascular risk factors such as hypertension, and affecting cardiac structure and function in the long term.
Nowadays, bariatric surgery is regarded as the most effective approach for weight loss, and the only approach for reducing obesity-related cardiovascular events.
However, the effect of different bariatric surgeries such as laparoscopic sleeve gastrectomy (LSG) or Roux-en-Y gastric bypass (RYGB) on cardiac function in patients with hypertension is still unclear.
Therefore, the aim of this study was to evaluate the benefit of different bariatric surgeries on cardiac structure and function echocardiography in patients with hypertension.
Study Type
Observational
Enrollment (Estimated)
40
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100050
- Beijing Friendship Hospital, Capital Medical University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
17 years to 70 years (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Obese patients with hypertension
Description
Inclusion Criteria:
- 18-70 years old
- BMI>24kg/m2
- Bariatric surgery patients of Beijing Friendship Hospital
- History of hypertension and treated with ≥2 antihypertensive drugs for more than 4 weeks
- No major barriers to provide written consent
Exclusion Criteria:
- Secondary hypertension, except because of sleep apnea
- cardiovascular disease (myocardial infarction, heart failure, stroke or coronary revascularization) within 6 months
- Severe concomitant diseases (autoimmune disease, malignancy, late stage of liver diseases, respiratory diseases and digestive diseases)
- Unable to understand or comply with the study procedures
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
LSG group
Laparoscopic sleeve gastrectomy (LSG) performed as a treatment for obesity
|
Laparoscopic sleeve gastrectomy (LSG) together with medical treatment aiming the control of cardiovascular risks including hypertension, diabetes mellitus or dyslipidemia.
|
RYGB group
Laparoscopic Roux-en-Y gastric bypass performed as a treatment for obesity
|
Roux-en-Y gastric bypass (LRYGB) together with medical treatment aiming the control of cardiovascular risks including hypertension, diabetes mellitus or dyslipidemia.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes on left ventricular ejection fraction (LVEF)
Time Frame: 12 months
|
Changes on LVEF in % assessed with the use of transthoracic echocardiography (TTE).
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes on left ventricular ejection fraction (LVEF)
Time Frame: 24 months
|
Changes on LVEF in % assessed with the use of TTE.
|
24 months
|
Changes on left ventricular end-diastolic diameter (LVEDD)
Time Frame: 12 months
|
Changes on LVEDD in mm assessed with the use of TTE.
|
12 months
|
Changes on left ventricular end-diastolic diameter (LVEDD)
Time Frame: 24 months
|
Changes on LVEDD in mm assessed with the use of TTE.
|
24 months
|
Major adverse cardiac events
Time Frame: 12 months
|
including all-cause mortality, cardiac death, acute myocardial infarction, stroke, heart failure, ventricular tachycardia or ventricular fibrillation requiring shock delivery.
|
12 months
|
Major adverse cardiac events
Time Frame: 24 months
|
including all-cause mortality, cardiac death, acute myocardial infarction, stroke, heart failure, ventricular tachycardia or ventricular fibrillation requiring shock delivery.
|
24 months
|
Changes on number of antihypertensive drugs
Time Frame: 12 months
|
Changes on of the total number of antihypertensive medications while maintaining office systolic and diastolic blood pressure <140 mm Hg and 90 mm Hg, respectively.
|
12 months
|
Changes on number of antihypertensive drugs
Time Frame: 24 months
|
Changes on of the total number of antihypertensive medications while maintaining office systolic and diastolic blood pressure <140 mm Hg and 90 mm Hg, respectively.
|
24 months
|
Changes on blood pressure
Time Frame: 12 months
|
Changes on systolic and blood pressure assessed with the use of 24-hour ABPM.
|
12 months
|
Changes on blood pressure
Time Frame: 24 months
|
Changes on systolic and blood pressure assessed with the use of 24-hour ABPM.
|
24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Rongchong Huang, M.D., Beijing Friendship Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 1, 2018
Primary Completion (Actual)
August 1, 2022
Study Completion (Estimated)
October 1, 2023
Study Registration Dates
First Submitted
December 12, 2021
First Submitted That Met QC Criteria
December 12, 2021
First Posted (Actual)
December 22, 2021
Study Record Updates
Last Update Posted (Actual)
August 8, 2023
Last Update Submitted That Met QC Criteria
August 6, 2023
Last Verified
August 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020-P2-254-02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
BayerCompletedPrimary HypertensionChina
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Addpharma Inc.Completed
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
China Academy of Chinese Medical SciencesGuang'anmen Hospital of China Academy of Chinese Medical SciencesCompletedHypertension, Resistant to Conventional Therapy | Primary HypertensionChina
-
Istituto Auxologico ItalianoRecruitingHypertension,Essential | Hypertension, UncontrolledArgentina, China
Clinical Trials on LSG
-
Mansoura UniversityCompletedGastroesophageal RefluxEgypt
-
Fabio GarofaloWithdrawnObesity | Gastroesophageal RefluxSwitzerland
-
Stefano TrastulliEthicon Endo-SurgeryActive, not recruitingType 2 Diabetes MellitusItaly
-
Jagiellonian UniversityCompleted
-
Mario Musella MDUnknownGastroesophageal Reflux | Morbid Obesity | Bariatric Surgery CandidateItaly
-
Sana Klinikum OffenbachCompletedPostoperative Complications | Other Complications of Other Bariatric ProcedureGermany
-
Shanghai 10th People's HospitalCompletedPolycystic Ovary SyndromeChina
-
Minia UniversityCompleted